A Research in Pharmacogenomics and Accurate Medication of New Antiplatelet Drug Ticagrelor
Phase of Trial: Phase IV
Latest Information Update: 23 Nov 2018
At a glance
- Drugs Ticagrelor (Primary)
- Indications Abdominal aortic aneurysm; Acute coronary syndromes; Cardiovascular disorders; Community-acquired pneumonia; Coronary artery disease; Sickle cell anaemia; Stroke
- Focus Adverse reactions; Pharmacogenomic
- 11 Nov 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 11 Nov 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.
- 06 Jun 2017 Status changed from not yet recruiting to recruiting.